General Information of Drug (ID: DM1JLUV)

Drug Name
10-Allyl-10H-dibenzo[b,f][1,4]oxazepin-11-one
Synonyms
10Allyl-DBOA-11one; 10-Ally-dibenz(b,f)(1,4)oxazepin-11-(10H)-one; 135810-46-7; 10-Ally-dibenz[b,f][1,4]oxazepin-11-(10H)-one; Dibenzoxazepinone 11; AC1L9R9L; CHEMBL301443; BDBM1972; DTXSID50159537; 5-allylbenzo[b][1,4]benzoxazepin-6-one; 5-prop-2-enylbenzo[b][1,4]benzoxazepin-6-one; 10-(2-Propenyl)dibenz[b,f][1,4]oxazepin-11(10H)-one
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 251.28
Topological Polar Surface Area (xlogp) 3.2
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C16H13NO2
IUPAC Name
5-prop-2-enylbenzo[b][1,4]benzoxazepin-6-one
Canonical SMILES
C=CCN1C2=CC=CC=C2OC3=CC=CC=C3C1=O
InChI
InChI=1S/C16H13NO2/c1-2-11-17-13-8-4-6-10-15(13)19-14-9-5-3-7-12(14)16(17)18/h2-10H,1,11H2
InChIKey
QANXXCPLBYYJSG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
453916
CAS Number
135810-46-7
TTD ID
D0A2SA

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 2. Tricyclic pyridobenzoxazepinones and dibenzoxazepinones. J Med Chem. 1992 May 15;35(10):1887-97.
2 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
3 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
4 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
7 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
8 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.